BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have been given an average rating of “Moderate Buy” by the nineteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $129.1250.

BNTX has been the subject of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Wells Fargo & Company cut their price target on BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. HC Wainwright reiterated a “buy” rating and set a $130.00 price objective on shares of BioNTech in a research note on Monday, April 27th. Berenberg Bank reduced their price objective on BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Finally, Canaccord Genuity Group decreased their price objective on BioNTech from $171.00 to $158.00 and set a “buy” rating for the company in a report on Wednesday, May 6th.

Insiders Place Their Bets

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the transaction, the chief operating officer directly owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.20% of the company’s stock.

Institutional Investors Weigh In On BioNTech

Hedge funds have recently bought and sold shares of the stock. Larson Financial Group LLC grew its stake in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the period. EFG International AG acquired a new position in shares of BioNTech in the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd boosted its holdings in BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after buying an additional 260 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares in the last quarter. Finally, Vestcor Inc acquired a new stake in BioNTech during the fourth quarter valued at $153,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

BNTX opened at $91.48 on Monday. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The firm has a 50 day moving average of $91.35 and a two-hundred day moving average of $97.83. The firm has a market capitalization of $23.13 billion, a PE ratio of -15.56 and a beta of 1.32.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, May 4th. The company reported ($2.26) EPS for the quarter, beating the consensus estimate of ($2.52) by $0.26. The business had revenue of $136.71 million for the quarter, compared to the consensus estimate of $207.42 million. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The business’s revenue for the quarter was down 35.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.73) EPS. On average, analysts anticipate that BioNTech will post -5.79 EPS for the current year.

BioNTech announced that its board has approved a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 4.2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.